在可切除的非小细胞肺癌中,新辅助化学免疫治疗的三年随访
Wenhao Ji1,2, Youhua Jiang3, Yuetong Li4
1Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Neoplasma
|March 20, 2024
概括
新辅助化疗免疫疗法对可切除的非小细胞肺癌 (NSCLC) 是有前途的,实现了高的病理完整反应率和有利的生存结果. 袖叶切除术是一种安全的手术选择,与这些患者的生存率改善有关.
科学领域:
- 胸部外科手术 胸部外科手术
- 医学瘤学 医学瘤学
- 癌症研究 癌症研究
背景情况:
- 新辅助化疗免疫治疗对于可切除的非小细胞肺癌 (NSCLC) 是至关重要的.
- 在袖叶切除术之前,新辅助化疗免疫疗法的影响仍然不清楚.
- 袖叶切除术是NSCLC的肺节省手术技术.
研究的目的:
- 评估新辅助化学免疫治疗在可切除NSCLC患者中的疗效和安全性.
- 分析手术方法,特别是袖叶切除术对结果的影响.
- 评估长期存活率和术后并发症.
主要方法:
- 从2018年12月到2020年12月,对56名可切除NSCLC患者 (IIB-IIIB阶段) 的回顾性研究.
- 分析疗效,安全性,病理完整反应 (pCR) 和下降阶段.
- 评估生存终点 (无事件生存[EFS],整体生存[OS]) 和术后并发症.
主要成果:
- 观察到高三年EFS (76.7%) 和OS (85.6%) 的比率.
- 病理完整反应 (pCR) 率为51.8%,85.7%的患者有显著的节点和瘤下降阶段.
- 与新辅助化疗免疫治疗相关的不良事件 (AE) 大多为1-2级 (61.4%),术后并发症发生在33.9%的患者中.
- 袖叶切除术与更好的生存结果有关,而不会增加手术困难或并发症.
结论:
- 新辅助化疗免疫疗法在可切除的NSCLC中显示出高PCR率和有利的长期存活率.
- 袖叶切除术是一种安全有效的手术选择,与改善生存率有关.
- 结合新辅助化学免疫疗法和袖叶切除术代表了对精选NSCLC患者的有前途的治疗策略.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...